Cellarity

Executive Summary

Cellarity is a biotechnology company that leverages a novel AI platform to discover therapeutics by targeting the dysfunctional cell states underlying disease. Unlike traditional drug discovery that focuses on individual molecular targets, Cellarity's approach integrates multi-omics data—particularly single-cell transcriptomics—to model disease biology and predict chemical interventions that restore healthy cell function. The company is advancing a pipeline of 'cell state-correcting' therapies initially focused on hematology and immunology. Based on its differentiated platform and early-stage pipeline, Cellarity represents an innovative approach to drug discovery, though it remains in a pre-revenue, preclinical stage with significant technical and regulatory risks. The company's success will depend on advancing candidates into clinical trials and demonstrating proof-of-concept in patients.

Upcoming Catalysts (preview)

• TBDLead Program IND Filing40% success
• TBDNew Platform Validation Data50% success
• TBDPartnership or Collaboration Announcement60% success